GLCCI1

GLCCI1 (glucocorticoid-induced 1) is a glucocorticoid receptor (GR)-inducible cytoplasmic protein that acts as an anti-apoptotic and anti-inflammatory effector across multiple epithelial and immune contexts (PMID:30860871, PMID:34504850). Mechanistically, GLCCI1 binds dynein light chain LC8 and p21-activated kinase 1 (PAK1) and inhibits PAK1 kinase activity toward LC8, promoting LC8 dimerization and suppressing pro-apoptotic Bim expression in thymocytes; its overexpression enlarges the thymus and its knockdown induces apoptosis (PMID:30860871). GLCCI1 protects against ER stress-induced apoptosis through a direct interaction with HSP90AB1, which in turn engages GRP78 to limit GRP78/CHOP/cleaved-CASP3 signaling (PMID:39496608). In the airway, GLCCI1 restrains pathological responses through several converging routes: it binds and downregulates WDR45B to suppress autophagosome formation (PMID:34050597), it maintains availability of the coactivator GRIP1 for GR rather than for competing IRF1/IRF3, thereby preserving GR-mediated anti-inflammatory signaling (PMID:34504850), and it acts via PI3K/AKT to restrain NLRP3 inflammasome activation in macrophages (PMID:39834584), suppress CCL5-driven eosinophil chemotaxis (PMID:41460639), and inhibit ZEB1-mediated epithelial-mesenchymal transition (PMID:41495772). GLCCI1 also serves a structural role in podocyte foot processes, where it colocalizes with nephrin and synaptopodin and is required for glomerular filtration barrier integrity (PMID:21949092, PMID:27174202). Common GLCCI1 promoter variants (rs37972/rs37973) reduce glucocorticoid-induced transcription of the gene and lower reporter activity, providing a functional basis for variable inhaled corticosteroid responses (PMID:21991891).

1. 2011 Medium

   Establishing why GLCCI1 matters clinically: promoter variants were shown to functionally reduce glucocorticoid-driven transcription, linking the locus to corticosteroid responsiveness.

   Evidence Luciferase reporter assay and genotype-expression correlation across populations

   PMID:21991891

   Open questions at the time

   • No mutagenesis or reconstitution defining the causal nucleotide
   • Does not establish the downstream protein function affected by reduced expression
2. 2011 Medium

   First in vivo function: GLCCI1 was localized to podocyte cytoplasm and shown by loss-of-function to be required for glomerular filtration barrier integrity, defining a structural/developmental role beyond steroid biology.

   Evidence RT-PCR/Western in mouse glomeruli; zebrafish morpholino knockdown with glomerular permeability assay

   PMID:21949092

   Open questions at the time

   • Molecular basis of podocyte structural contribution unknown
   • Morpholino phenotype not confirmed with stable genetic mutant
3. 2016 Medium

   Placed podocyte GLCCI1 expression within signaling: it colocalizes with nephrin/synaptopodin and its hyperglycemia-driven loss is PI3K-dependent, connecting GLCCI1 abundance to PI3K signaling.

   Evidence Immunofluorescence, immunoelectron microscopy, wortmannin treatment in high-glucose podocytes and diabetic rats

   PMID:27174202

   Open questions at the time

   • Whether PI3K regulates GLCCI1 transcriptionally or post-translationally unresolved
   • No functional rescue of podocyte phenotype shown
4. 2019 High

   Defined the core molecular mechanism: GLCCI1 binds LC8 and PAK1 and inhibits PAK1 kinase activity to promote LC8 dimerization and suppress Bim, establishing it as a GR-downstream anti-apoptotic mediator.

   Evidence Co-IP, PAK1 kinase activity assay, thymocyte knockdown, GLCCI1 transgenic mice, microtubule colocalization in QBI293A cells

   PMID:30860871

   Open questions at the time

   • Structural basis of GLCCI1-PAK1/LC8 binding not determined
   • Phosphorylation site directing microtubule localization not mapped
5. 2021 Medium

   Extended GLCCI1 to airway autophagy control: it binds and downregulates WDR45B to suppress autophagosome formation, with WDR45B rescue confirming epistasis in asthma models.

   Evidence Co-IP and WDR45B rescue in vitro and in OVA asthma mice

   PMID:34050597

   Open questions at the time

   • How GLCCI1 represses WDR45B expression mechanistically unknown
   • Single lab
6. 2021 Medium

   Explained GLCCI1's contribution to steroid sensitivity: it preserves GRIP1 coactivator availability for GR by limiting IRF1/IRF3 competition, mechanistically tying GLCCI1 loss to blunted anti-inflammatory signaling.

   Evidence Reciprocal Co-IP (GRIP1:GR/IRF1/IRF3), GLCCI1-/- mice and siRNA in Beas2B/A549 cells

   PMID:34504850

   Open questions at the time

   • Direct molecular partner of GLCCI1 in this circuit not identified
   • Whether effect is transcriptional or via protein stability unclear
7. 2023 Medium

   Showed isoform diversity with conserved function: a testis spermatid-specific GLCCI1-short isoform retains LC8 binding and is estrogen-receptor regulated, expanding the anti-apoptotic mechanism to a new tissue.

   Evidence Western isoform identification, Co-IP (GLCCI1-short:LC8), ERα-dependent luciferase reporter

   PMID:36468710

   Open questions at the time

   • Functional role of the short isoform in spermatogenesis not tested
   • Whether short isoform also binds PAK1 unknown
8. 2024 Medium

   Identified a chaperone-linked anti-apoptotic route: GLCCI1 interacts with HSP90AB1, which engages GRP78, to suppress ER stress-induced apoptosis in retinal ganglion cells under hyperglycemia.

   Evidence Co-IP (GLCCI1:HSP90AB1, HSP90AB1:GRP78), gain/loss-of-function in RGCs, diabetic retinopathy mouse model

   PMID:39496608

   Open questions at the time

   • How GLCCI1 regulates HSP90AB1 (binding vs. stability) unresolved
   • Single lab
9. 2024 Medium

   Placed GLCCI1 in inflammasome control: GLCCI1 acts downstream/parallel to PI3K/AKT to restrain NLRP3 activation in macrophages, with KO and adoptive transfer establishing necessity.

   Evidence Glcci1-/- mice, BMDM adoptive transfer, LY294002 and MCC950 treatments, Western blotting

   PMID:39834584

   Open questions at the time

   • Direct molecular link between GLCCI1 and NLRP3 not defined
   • Whether GLCCI1 acts on priming or assembly unknown
10. 2025 Medium

    Connected GLCCI1 to mitochondrial protection: it activates a DYRK1A/FAM117B axis that stabilizes NRF2 by inhibiting its ubiquitination, reversing OVA-induced mitochondrial dysfunction.

    Evidence Gain-of-function in OVA mice and BECs, NRF2 ubiquitination assay, mitochondrial function readouts

    PMID:40490147

    Open questions at the time

    • Direct physical interaction of GLCCI1 with DYRK1A/FAM117B not shown
    • Single lab
11. 2026 Medium

    Linked GLCCI1 loss to eosinophilic inflammation: deficiency upregulates CCL5 via AKT to drive eosinophil chemotaxis, with CCL5 inhibition rescuing the phenotype.

    Evidence RNA-Seq, siRNA in BEAS-2B, transwell chemotaxis, CCL5 inhibition, Glcci1-/- OVA mice

    PMID:41460639

    Open questions at the time

    • Mechanism connecting GLCCI1 to AKT-driven CCL5 transcription unknown
    • Single lab
12. 2026 Medium

    Defined an anti-EMT function: GLCCI1 activates PI3K/AKT/mTOR to inhibit ZEB1-mediated EMT in airway epithelium, with ZEB1 overexpression and pathway inhibitors confirming the order.

    Evidence Gain-of-function in OVA mice and TNF-α-treated BEAS-2B, ZEB1 rescue, PI3K/mTOR inhibitors, Western blotting

    PMID:41495772

    Open questions at the time

    • Direct GLCCI1 effectors upstream of PI3K not identified
    • Single lab

• How GLCCI1's diverse activities — LC8/PAK1 binding, chaperone interactions, autophagy and inflammasome suppression, and multiple PI3K/AKT-linked outputs — are integrated into a single coherent biochemical function remains unresolved.
• No structural model or defined catalytic/adaptor activity for GLCCI1
• Whether the PI3K/AKT effects share a common molecular node is unknown
• Direct partners in inflammasome, CCL5, and NRF2 circuits not physically mapped